CLDX vs DNTH
CLDX: A clinical-stage biopharmaceutical company developing mast cell-targeted monoclonal and bispecific antibodies for chronic urticaria, inflammatory skin diseases, and systemic inflammatory conditions. DNTH: Dianthus Therapeutics is a clinical-stage biopharmaceutical company developing targeted complement-pathway inhibitors to treat severe autoimmune and inflammatory diseases.
Side-by-side fundamentals
| Metric | CLDX | DNTH | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $34.77 | $102.76 | |
| Market cap as of 2026-07-23 | $2.7B | $5.7B | |
| PEG as of 2026-07-23 | -0.14 | -0.59 | DNTH lower |
| Net margin as of 2026-07-23 | -25011.8% | -12998.5% | DNTH higher |
| Gross margin as of 2026-07-23 | +17.6% | n/a | |
| Operating margin as of 2026-07-23 | -27187.6% | -14318.0% | DNTH higher |
| ROE as of 2026-07-23 | -50.7% | -27.3% | DNTH higher |
| ROA as of 2026-07-23 | -46.6% | -25.9% | DNTH higher |
| Debt / equity as of 2026-07-23 | 0.00 | 0.00 | Tie |
| Revenue growth (YoY) as of 2026-07-23 | -88.5% | -79.5% | DNTH higher |
| Revenue CAGR (3y) SEC XBRL | -13.1% | n/a | |
| Dividend streak (yrs) SEC XBRL | n/a | 0 | |
| Beta as of 2026-07-23 | 0.82 | 1.75 | |
| 1-year return as of 2026-07-22 close | +55.5% | +409.7% | DNTH higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.